LERAM pharmaceuticals

What LERAM pharmaceuticals does

LERAM pharmaceuticals s.r.o. is a privately-held Czech pharmaceutical company headquartered in Brno-Bystrc (Páteřní 1216/7) and established in 2016 by industry experts with more than two decades of experience spanning oncology, specialty pharma, dermatology, CNS, urology, and OTC. It operates as the pharmaceutical arm of the broader LERAM GROUP network (alongside LERAM Medical, LERAM dental, LERAM estate, LERAM building, LERAM gastro) and concentrates on meeting the needs of patients, physicians, pharmacists, and business partners through in-licensing and product acquisition.

The company distributes a diversified portfolio of prescription medications, medical devices, and dietary supplements across five therapeutic areas: oncology and hematology (LODRONAT/clodronate for multiple myeloma, anagrelid Leram for essential thrombocythemia, Gelclair for oral mucositis, Neuritogen dietary supplement); orthopedics (Durolane, ChondroCross, SingJoint, ChondroFiller liquid, Recovertendo CTP, ChondroPlus CTP, nStride APS, GPS III Platelet Concentration System, ASU 300 LERAM, Hyaluamin Strong, Nimesulid Leram, PRONTOFLEX, Condrodin); wound healing (L-Mesitran medical-honey line distributed since 2017, Aqvitox Flowfiber AG antimicrobial dressings); surgery and intensive care (ProveDye, ProvEndo, Methylthioniniumchlorid Proveblue for methemoglobinemia); and genomic testing (Agendia's MammaPrint 70-gene and BluePrint 80-gene breast cancer assays). Products are sourced from international partners including Agendia, Helsinn Healthcare, Provepharm, Riemser, Zimmer Biomet, Bioventus, URGO, and Bluepharma.

LERAM generates revenue through in-licensing royalties, one-time product acquisitions, and marketing contracts (including co-promotion of mature/unsupported brands), executing full-service capabilities — sales, marketing, registration, market access, pharmacovigilance, medical information, business development, customer service, logistics, and storage — for partners across the Czech Republic and Central Europe. Distribution is via pharmacy and healthcare-provider networks, supported by medical-conference and medical-education outreach. No public pricing, revenue, or funding figures are disclosed.

Name

LERAM pharmaceuticals

Legal name

LERAM pharmaceuticals s.r.o.

Website

https://leram-pharma.cz

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

LERAM pharmaceuticals s.r.o. is a privately-held Czech in-licensing pharmaceutical distributor, founded in 2016, that markets prescription drugs, medical devices, and dietary supplements across oncology, hematology, orthopedics, wound healing, surgery, and genomic testing to patients, physicians, and pharmacists in the Czech Republic and Central Europe.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAAAB

Specialty Care Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYCRAOAHAB

OTC Medicines & Consumer Health Products Distribution

Consumer Products & Retail/Wholesale, Distribution & Category Management/Health, OTC & Pharmacy Wholesale Distribution

SECONDARYHLAGAMAD

Specialty Pharma & Biologics Distribution (GDP-compliant)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences

SECONDARYHSABALAM

OTC, Vitamins & Supplement Management

Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support

Keywords

• Pharmaceutical distribution
• Specialty pharmaceuticals
• In-licensing services
• Medical device distribution
• Oncology products

Headquarters

HQ city

Brno

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. In-licensing: Obtaining rights to international partners' products for sale in the Czech Republic and other Central European markets. The company arranges all necessary activities including registration and market access.
2. Product Acquisition: Purchasing all rights essential for sales of products targeted to the Czech market and neighboring countries.
3. Local In-Licensing: Obtaining rights to products from other Czech manufacturers for distribution.
4. Marketing Contracts: Investing in mature and unsupported brands to increase sales and profit through innovative marketing strategies including co-promotion.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

LERAM pharmaceuticals s.r.o. is a privately-held Czech pharmaceutical company that distributes prescription medications, OTC medications, medical devices, and dietary supplements across Oncology and Hematology, Orthopedics, Surgery and Intensive Care, and Wound Healing therapeutic areas. The company primarily operates through in-licensing international pharmaceutical products for the Czech Republic and Central European markets, providing full-service capabilities including registration, market access, sales, marketing, pharmacovigilance, logistics, and storage.

Product overview

LERAM pharmaceuticals is a Czech privately-held pharmaceutical company offering a diversified portfolio of prescription medications, medical devices, and dietary supplements across four main therapeutic areas: Oncology and Hematology (including genomic testing with MammaPrint® and BluePrint®, supportive cancer treatment medications like LODRONAT and anagrelid, wound care products including Gelclair® and L-Mesitran, and dietary supplements like Neuritogen®); Orthopedics (hyaluronic acid injections such as Durolane®, ChondroCross, SingJoint®, cartilage repair products like ChondroFiller liquid®, platelet concentration systems including GPS® III and nStride APS®, and anti-inflammatory medications); Surgery and Intensive Care (surgical dyes like ProveDye and ProvEndo, methylene blue preparations for methemoglobinemia treatment); and Wound Healing (antimicrobial dressings like Aqvitox Flowfiber AG, medical honey-based products in the L-Mesitran line). The company operates through in-licensing arrangements, product acquisitions, and marketing contracts, serving the Czech Republic and Central European markets.

Differentiator

Problem solved

Functional benefit

Products and services

• MammaPrint FDA-approved genomic test analyzing 70 genes associated with breast cancer recurrence, classifying patients as low or high risk of metastasis within 10 years of diagnosis. Helps physicians and patients make definitive treatment decisions.
• BluePrint Genomic test predicting breast tumor behavior through analysis of 80 gene activity, enabling stratification into luminal, HER2, or basal subtypes. Results available within 10 days.
• LODRONAT 520 mg Bisphosphonate medication containing clodronic acid for supportive treatment of patients with multiple myeloma and bone metastases from solid tumors. Also used for hypercalcemia treatment.
• anagrelid Leram 0.5 mg Medication for reducing elevated platelet counts in patients with essential thrombocythemia.
• Neuritogen Dietary supplement containing curcumin, resveratrol, Mangifera indica extract and vitamins B2, B6 in enhanced absorption form. Supports protection of nervous system cells, available in pharmacies without prescription.
• L-Mesitran Innovative wound care product line based on medical honey (20-48%) combined with medical hypoallergenic lanolin, vitamins C and E. Includes ointments, gels, and dressings for treating acute and chronic wounds including burns, pressure ulcers, leg ulcers, and diabetic ulcers.
• Aqvitox Flowfiber AG Antimicrobial wound dressing with silver ions indicated for treatment of moderately to heavily exuding wounds. Creates moist wound environment and provides sustained silver release for antimicrobial protection.
• Durolane Single-injection hyaluronic acid (NASHA) treatment for relieving pain caused by osteoarthritis. Provides joint lubrication and mobility improvement.
• Recovertendo CTP Periarticular injection containing biocompatible hyaluronic acid BHA in complex with synthetic collagen tripeptide CTP for joint treatment.
• ChondroFiller liquid Biological cartilage implant. Biological collagen matrix for regeneration of joint cartilage.
• Condrodin Pure chondroitin sulfate of bovine origin for osteoarthritis treatment.
• ChondroPlus CTP Single-dose injection with collagen for immediate application in joint treatment.
• ChondroCross Stabilized hyaluronic acid with higher concentration and molecular weight for symptomatic treatment of osteoarthritis.
• nStride APS Kit for preparation of autologous blood plasma for treatment of osteoarthritis.
• GPS III Platelet Concentration System High-yield platelet concentration system for separating patient's own blood components through centrifugation to produce concentrated platelet-rich plasma (PRP).
• SingJoint Hyaluronic acid injection for joint treatment.
• ASU 300 LERAM Dietary supplement containing avocado and soybean extract (ASU) and vitamin C. Contributes to collagen formation for normal cartilage and bone function.
• Hyaluamin Strong Combination of dual hyaluronic acid and amino acids for advanced joint lubrication and direct cartilage regeneration support.
• Nimesulid Leram 100 mg Peripherally and centrally acting analgesic, anti-inflammatory with fast onset of action (15 minutes). COX2 preferential NSAID for acute pain treatment.
• PRONTOFLEX 10% Non-steroidal anti-rheumatic spray for local application for treatment of pain and swelling from bruises, sprains, joint injuries, back pain, and rheumatic pain.
• ProveDye First dye containing 0.5% methylene blue in accordance with European Pharmacopoeia, designed for visualization during surgical procedures.
• ProvEndo Indigo carmine. Sterile marker for gastrointestinal endoscopy. Aid for visualization of polypoid or flat lesions including adenomas.
• Methylthioniniumchlorid Proveblue 5 mg/ml Highly purified methylene blue solution for intravenous injection for treatment of acute symptomatic methemoglobinemia caused by medicinal and chemical preparations. First methylene blue suitable for children.
• Gelclair Viscous concentrated oral gel for treatment of painful symptoms of oral mucositis caused by chemotherapy and radiotherapy. Creates protective film over exposed nerve endings providing pain relief.

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core.

• AgendiacoreTechnology or IntegrationProvider of MammaPrint and BluePrint genomic tests for breast cancer treatment decision support, distributed by Leram Pharmaceuticals.
• Helsinn HealthcarecoreTechnology or IntegrationManufacturer of Gelclair for treatment of oral mucositis, distributed by Leram Pharmaceuticals in Czech Republic.
• L-MesitrancoreTechnology or IntegrationInnovative product line based on medical honey for wound treatment, distributed by Leram Pharmaceuticals in Czech Republic since 2017.
• ProvepharmcoreTechnology or IntegrationManufacturer of Methylthioniniumchlorid Proveblue for treatment of methemoglobinemia, distributed by Leram Pharmaceuticals.
• RiemsercoreTechnology or IntegrationMarketing authorization holder for Lodronat (clodronate) for supportive treatment of multiple myeloma and bone metastases.
• Zimmer BiometcoreTechnology or IntegrationManufacturer of GPS III Platelet Concentration System and Durolane for orthopedics, distributed by Leram Pharmaceuticals.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Zentiva: Czech-headquartered specialty and generic pharmaceutical company with broad CEE presence. Directly comparable as a domestic Czech pharma operator covering both prescription drugs and consumer health, with similar geographic footprint.
• STADA Arzneimittel AG: European specialty and generic pharma group with strong CEE footprint via acquisitions. Comparable in business model mix of in-licensing, specialty pharma, and OTC/consumer health distribution across Central Europe.
• KRKA: Slovenian specialty and generic pharma manufacturer with significant CEE and Eastern European sales. Comparable as a regional specialty pharma player distributing through similar pharmacy and provider channels in overlapping CE markets.
• Gedeon Richter: Hungarian specialty pharma company with strong presence in CEE, including oncology, women's health, and CNS. Comparable as a CE-based specialty pharma distributor targeting similar prescriber base and hospital channels.
• Recordati Industria Chimica e Farmaceutica S.p.A. Italian specialty pharma group operating across Europe with focus on niche and specialty therapeutics. Comparable business model combining in-licensing of specialty brands with direct sales infrastructure in CE/EU markets.
• Ewopharma d.o.o. Slovenia-headquartered specialty pharma distributor focusing on Central and Eastern Europe. Highly comparable as a regional in-licensor bringing innovative prescription and consumer health products to CE markets.
• Polpharma S.A. Polish pharmaceutical group with broad CEE distribution and specialty/generic portfolio. Comparable in scale and regional footprint, serving pharmacy and hospital channels across Central Europe.
• Hikma Pharmaceuticals PLC: UK-headquartered specialty/generic pharma with extensive EMEA distribution. Comparable business model combining in-licensed brands, specialty pharma, and hospital-focused generics across European markets.

Broad incumbents

• Almirall S.A. Spanish specialty pharma company focused on dermatology and specialty therapeutics across Europe. Comparable specialty pharma focus though broader portfolio and larger scale than LERAM.

Emerging players

• Medochemie Ltd. Cyprus-based pharma manufacturer and distributor with growing CE and emerging Europe presence. Comparable as a regional specialty/generic pharma distributing prescription drugs and consumer health products across multiple CE markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCpjU3RnQgH8ZM7Fdv2n9dbg
• Facebookfacebook.com/rychlehojeniran
• LinkedInlinkedin.com/company/leram-pharmaceuticals-s.r.o.

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LERAM pharmaceuticals